Search Results - clinical+and+disease+specializations+%3e+neurology+%3e+hiv-associated+neurocognitive+disorders

3 Results

Sort By:

Methods to Treat Neurodegenerative Diseases

Unmet NeedAn estimated 930K people in the US are living with a neurodegenerative disease (Alzheimer’s and Parkinson’s are most common). However, current standard of care treatments mostly addresses symptoms of these diseases. To date no disease modifying or neuroprotective treatments are approved for Parkinson, and only 1 recently has been for Alzheimer’s...

Published: 5/10/2024 | Inventor(s): Rana Rais, Barbara Slusher, Arindom Pal

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Multiple Sclerosis, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders

Acetylated Polyamines as Biomarkers of HIV-1 Associated Neurocognitive Disorders (HAND)

Acetylated Polyamines as Biomarkers of HIV-1 Associated Neurocognitive Disorders (HAND) Marketing Summary: Polyamines are molecules, present in all organisms, whose concentrations are regulated by the enzyme Spermine/Spermidine Acetyl transferase (SSAT). SSAT works by inactivating polyamines. Once these polyamines are inactivated they are...

Published: 5/9/2024 | Inventor(s): Kamel Khalili, Carlos Barrero, Salim Merali, Jay Rappaport, Norman Haughey, Ned Sacktor

Keywords(s): Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Cognitive Impairment, Diagnostic Biomarker, Disease Indication, HIV/AIDS, HIV-Associated Neurocognitive Disorders, In Vitro Diagnostics

Category(s): Clinical and Disease Specializations, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders

Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs

Some glutamine antagonists have been shown to have anti-cancer activities in multiple preclinical and clinical studies. However the toxicity of the glutamine antagonists at doses necessary for their anticancer effects have hampered their clinical development. Herein we describe a completely novel use for the glutamine antagonists. Using a prototype...

Published: 5/9/2024 | Inventor(s): Barbara Slusher, David Volsky, Kristen Hollinger, Michael Nedelcovych, Atsushi Kamiya

Keywords(s): Antagonists/Inhibitors, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, HIV/AIDS, HIV-Associated Neurocognitive Disorders, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > HIV/AIDS, Clinical and Disease Specializations > Neurology > Cognitive Impairment, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities